FMC Corporation — Q1 2024 Form 10-Q Summary
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. FMC is a global agricultural sciences company operating as one reportable segment. Interim financial statements are unaudited and were reviewed by KPMG.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Revenue | $918.0 million | $1,344.3 million | Down 32% reported; down 31% organically |
| Gross margin | $339.7 million; 37% of revenue | $581.3 million; 43% | Down $241.6 million; lower volume and pricing were partly offset by input-cost improvement |
| Operating profit | $74.0 million | $304.5 million | Includes restructuring and other charges |
| Continuing-operations income | $9.4 million | $207.4 million | GAAP |
| Net income (loss) attributable to FMC stockholders | $(2.7) million; $(0.02) diluted EPS | $196.0 million; $1.55 diluted EPS | Q1 2024 includes a $12.5 million discontinued-operations loss |
| Adjusted EBITDA | $160.6 million | $361.7 million | Down 56%; non-GAAP |
| Adjusted after-tax earnings from continuing operations attributable to stockholders | $45.4 million | $223.1 million | Down about 80%; non-GAAP |
| Operating cash flow, continuing operations | $(142.9) million | $(851.3) million | Seasonal working-capital outflows remained substantial |
| Free cash flow | $(187.8) million | $(915.2) million | Non-GAAP |
Revenue fell across all regions: North America declined 48%, Latin America 20%, EMEA 20%, and Asia 29%. Management attributed the broad-based pressure mainly to ongoing channel destocking, which reduced volumes; pricing was also a headwind, particularly in Latin America and Asia. Management cited poor weather in China and India and registration removals and product rationalization in EMEA. New products and branded diamides provided some regional support.
SG&A declined 12% to $163.9 million and R&D declined 22% to $60.9 million, mainly reflecting cost-reduction and mitigation actions. FMC said R&D reductions did not sacrifice investment in Plant Health or its new active-ingredient pipeline. Net interest expense rose 20% to $61.7 million, primarily from higher rates and short-term debt balances. Restructuring and other charges increased to $40.9 million from $12.5 million.
Balance sheet, debt and liquidity
- At March 31, 2024, cash was $417.8 million, total debt was $4.34 billion, and total equity was $4.33 billion. Cash at December 31, 2023 was $302.4 million; total debt then was $3.96 billion.
- Short-term debt and current maturities totaled $1.31 billion, including $1.11 billion of commercial paper. Long-term debt, excluding current maturities, was $3.02 billion.
- FMC reported $639.6 million of remaining borrowing capacity under its revolving credit facility and said it had adequate near-term liquidity. It was in compliance with debt covenants; four-quarter leverage was 5.71 versus a 6.50 maximum, and interest coverage was 3.08 versus a 2.50 minimum.
- Customer advance payments declined to $88.7 million from $482.1 million at year-end, while accrued customer rebates rose to $669.3 million from $480.9 million. The company cited seasonal timing and lower prior-year sales in explaining working-capital movements.
- Q1 investing cash outflow was $23.7 million, including $20.7 million of capital expenditures. Financing provided $305.7 million, chiefly reflecting increased short-term debt. FMC paid $72.5 million in dividends.
Material changes, outlook and management commentary
- Management expects 2024 revenue of $4.50–$4.70 billion, adjusted EBITDA of $900 million–$1.05 billion, and adjusted diluted EPS of $3.23–$4.41. The revenue outlook assumes the crop protection market is flat to down low-single digits, with new-product growth primarily in the second half. The company did not provide a GAAP earnings forecast, citing unpredictable components.
- FMC expects 2024 free cash flow of $400–$600 million and adjusted cash from operating activities of $670–$850 million. Management cited expected rebuilding of payables and lower inventory as significant drivers of the year-over-year improvement. Both are non-GAAP measures.
- Project Focus, launched in response to the market downturn and destocking, is expected to generate $50–$75 million of adjusted EBITDA contribution in 2024 and at least $150 million of annual run-rate savings by the end of 2025. The company expects total pretax restructuring charges of $180–$215 million; estimated 2024 Project Focus cash spending is $70–$90 million. Execution is expected to finish by the end of 2025.
- As a subsequent event, FMC finalized an agreement in Q2 2024 to exit a contract manufacturer. It expects a non-cash write-off of about $53 million in Q2, with no other cash charges associated with the termination.
- FMC plans to sell its non-crop Global Specialty Solutions business as part of Project Focus. Potential sale proceeds are excluded from the cash-flow outlook; if completed, FMC expects to use them to reduce debt.
- Share repurchases under the public authorization are suspended until September 30, 2025 under the credit-agreement amendment; none were made under the program in Q1. The company expects to continue quarterly dividends, subject to Board approval and relevant factors.
Risks, contingencies and unusual items
- Environmental reserves, net of expected recoveries, were $574.0 million at March 31, 2024. Estimated reasonably possible environmental losses exceed accrued amounts by approximately $240 million. FMC said unreserved obligations may materially affect future quarterly or annual results, although it does not expect them to materially adversely affect liquidity or financial condition because payments may extend over many years.
- Discontinued operations generated a $12.5 million loss, mainly from retained environmental and legal liabilities and other legacy obligations. FMC reported $21.5 million of cash outflow from discontinued-operations activities in Q1.
- On March 28, 2024, a Beijing court dismissed FMC’s challenge to the invalidation of one Chinese patent related to a chemical intermediate used to produce chlorantraniliprole. FMC appealed to China’s Supreme People’s Court. The patents remain valid but unenforceable pending appeal; a separate appeal remained unresolved.
- Debt is exposed to interest-rate changes: 72% was fixed-rate and 28% variable-rate at quarter-end. A one-percentage-point rate increase would have increased quarterly gross interest expense by an estimated $3.0 million, based on the reported variable-rate debt position.
- FMC disclosed significant foreign-exchange exposure and uses derivatives to manage currency, commodity and interest-rate risks. It reported a net financial-instrument liability of $2.5 million at quarter-end. No open commodity contracts or interest-rate swaps were outstanding.
- The company reported no significant updates to the contingencies discussed in its 2023 Form 10-K. Management said disclosure controls were effective and reported no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether channel destocking has eased and whether the anticipated second-half market recovery and new-product growth materialize.
- Progress toward 2024 guidance, especially margins, adjusted EBITDA, free cash flow and working-capital assumptions.
- Project Focus costs, cash spending, savings delivery, and any additional inventory, asset-write-off or contract-termination charges.
- Commercial paper refinancing needs, available facility capacity, debt-covenant headroom and the impact of interest rates on debt service.
- Changes in environmental estimates, claims and remediation spending, including the approximately $240 million reasonably possible exposure above accruals.
- Developments in the Chinese patent appeals and potential effects on FMC’s diamide business and enforcement strategy.
- Completion and proceeds of the planned Global Specialty Solutions sale, which are not included in the stated free-cash-flow outlook.